Vaccine Therapy and Interleukin-12 With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma - Related Studies

Vaccine Therapy and Interleukin-12 With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

This study is ongoing, but not recruiting participants.

Study NCT00064168. Last updated on May 23, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Melanoma (Skin)

2	Additional conditions recognized in this trial
		Melanoma

3	More general conditions related to this trial
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms, Germ Cell and Embryonal
		Neoplasms, Nerve Tissue
		Neuroectodermal Tumors
		Neuroendocrine Tumors
		Nevi and Melanomas

4	Interventions listed in this trial
		MART-1 antigen
		NA17-A antigen
		aldesleukin
		gp100 antigen
		recombinant MAGE-3.1 antigen
		recombinant interleukin-12
		therapeutic autologous lymphocytes

5	Additional drug interventions recognized in this trial
		Interleukin-12

6	More general drug interventions related to this trial
		Adjuvants, Immunologic
		Angiogenesis Inhibitors
		Angiogenesis Modulating Agents
		Anti-HIV Agents
		Anti-Infective Agents
		Anti-Retroviral Agents
		Antineoplastic Agents
		Antiviral Agents
		Growth Inhibitors
		Growth Substances
		Immunologic Factors
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

7	Sponsors listed in this trial
		University of Chicago
		National Cancer Institute (NCI)